Have a personal or library account? Click to login
Comparison of albendazole cytotoxicity in terms of metabolite formation in four model systems Cover

Comparison of albendazole cytotoxicity in terms of metabolite formation in four model systems

Open Access
|Sep 2017

References

  1. 1. Baillie T.A.: Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 2008, 21, 129-137.10.1021/tx7002273
  2. 2. Baliharová V., Skálová L., Maas R.F.M., De Vrieze G., Bull S., Fink-Gremmels J.: The effects of benzimidazole anthelmintics on P4501A in rat hepatocytes and HepG2 cells. Res Vet Sci 2003, 75, 61-69.10.1016/S0034-5288(03)00033-X
  3. 3. Capece B.P.S., Navarro M., Arcalis T., Castells G., Toribio L., Perez F., Carretero A., Ruberte J., Arboix M., Cristòfol C.: Albendazole sulphoxide enantiomers in pregnant rats embryo concentrations and developmental toxicity. Vet J 2003, 165, 266-275.10.1016/S1090-0233(02)00158-2
  4. 4. Capece B.P.S., Virkel G.L., Lanusse C.E.: Enantiomeric behaviour of albendazole and fenbendazole sulfoxides in domestic animals: pharmacological implications. Vet J 2009, 181, 241-250.10.1016/j.tvjl.2008.11.01019124257
  5. 5. Capleton A.C., Courage C., Rumsby P., Holmes P., Stutt E., Boxall B.A., Levy L.S.: Prioritising veterinary medicines according to their potential indirect human exposure and toxicity profile. Toxicol Lett 2006, 163, 213-223.10.1016/j.toxlet.2005.10.02316513297
  6. 6. Castell J.V., Jover R., Martinez-Jiménez C.P., Gómez- Lechón M.J.: Hepatocyte cell lines: their use, scope, and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2006, 2, 183-212.10.1517/17425255.2.2.18316866607
  7. 7. Coecke S., Ahr H., Blaauboer B.J., Bremer S., Castell J., Combes R., Corvi R., Crespi C.L., Cunningham M.L., Elaut G., Eletti B., Freidiq A., Gennari A., Ghersi-Egea J.F., Guillouzo A., Hartung T., Hoet P., Ingelman-Sundberg M., Munn S., Janssens W., Ladstetter B., Leahy D., Long A., Meneguz A., Monshouwer M., Morath S., Nagelkerke F., Pelkonen O., Ponti J., Prieto P., Richert L., Sabbioni E., Schaack B., Steiling W., Testai E., Vericat J.A., Worth A.: Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM Workshop 54. Altern Lab Anim 2006, 34, 49-84.10.1177/02611929060340011316522150
  8. 8. Cristòfol C., Navarro M., Franquelo C., Valladares J.E., Carretero A., Ruberte J., Arboix M.: Disposition of netobimin, albendazole, and its metabolites in the pregnant rat: developmental toxicity. Toxicol Appl Pharmacol 1997, 144, 56-61. 9. Dayan A.D.: Albendazole, mebendazole, and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 2003, 86, 141-159. 10.1006/taap.1997.81149169069
  9. 10. Delatour P., Benoit E., Besse S., Boukraa A.: Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs, and rats. Xenobiotica 1991, 21, 217-221.10.3109/004982591090394632058177
  10. 11. Delatour P., Benoit E., Caude M., Tambute A.: Species differences in the generation of the chiral sulfoxide metabolite of albendazole in sheep and rats. Chirality 1990, 2, 156-160.10.1002/chir.5300203062147560
  11. 12. Delatour P.: Some aspects of the teratogenicity of veterinary drugs. Vet Res Commun 1983, 7, 125-131.10.1007/BF02228606
  12. 13. Donato M.T., Jover R., Gómez- Lechón M.J.: Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr Drug Metab 2013, 14, 946-968.10.2174/1389200211314090002
  13. 14. Donato M.T., Lahoz A., Castell J.V., Gómez-Lechón M.J.: Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 2008, 9, 1-11.10.2174/138920008783331086
  14. 15. European Medicines Evaluation Agency (EMEA). Albendazole (Extrapolation to all ruminants) Summary Report. EMEA/MRL/865/03-Final. 2004. Available from: http://www.emea.eu.int.
  15. 16. Gad S.C.: Active drug metabolites in drug development. Curr Opin Pharmacol 2003, 3, 98-100.10.1016/S1471-4892(02)00003-6
  16. 17. Hennessy D.R., Sangster N.C., Steel J.W., Collins G.H.: Comparative pharmacokinetic behavior of albendazole in sheep and goats. Int J Parasitol 1993, 23, 321-325.10.1016/0020-7519(93)90006-K
  17. 18. Křižová-Forstová V., Lamka J., Cvilink V., Hanušová V., Skálová L.: Factors affecting pharmacokinetics of benzimidazole anthelmintics in food-producing animals: the consequences and potential risks. Res Vet Sci 2011, 91, 333-341.10.1016/j.rvsc.2010.12.013
  18. 19. Mosmann T.: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65, 55-63.10.1016/0022-1759(83)90303-4
  19. 20. Radko L., Minta M., Stypuła-Trębas S.: Differential toxicities of albendazole and its two main metabolites to Balb/c 3T3, HepG2, FaO lines and rat hepatocytes. J Vet Res 2016, 60, 495-502.10.1515/jvetres-2016-0073
  20. 21. Rodriges R.M., Bouhifd M., Bories G., Sacco M.G., Gribaldo L., Fabbri M., Coecke S., Whelan M.P.: Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells. Toxicol in Vitro 2013, 27, 760-767.10.1016/j.tiv.2012.12.00423261643
  21. 22. Rolin S., Souhaili-el Amri H., Batt A.M., Levy M., Bagrel D., Siest G.: Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatoma cell lines. Cell Biol Toxicol 1989, 5, 1-14.10.1007/BF001410602563953
  22. 23. Schoonen W.G.E.J., de Roos J.A.D.M., Westerink W.M.A., Débiton E.: Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1, and CHO cells. II Mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol in Vitro 2005, 19, 491-503.10.1016/j.tiv.2005.01.002
  23. 24. Schoonen W.G.E.J., Westerink W.M.A., de Roos J.A.D.M., Débiton E.: Cytotoxic effects of 100 reference compounds on HepG2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I Mechanistic assays on ROS, glutathione depletion, and calcein uptake. Toxicol in Vitro 2005, 19, 505-516.10.1016/j.tiv.2005.01.003
  24. 25. Seglen P.O.: Preparation of isolation rat liver cells. Methods Cell Biol 1976, 13, 29-83.10.1016/S0091-679X(08)61797-5
  25. 26. Teruel M.T., Felipe A.E., Solana H.D., Sallovitz J.M., Lanusse C.E.: Placental and fetal toxicity of albendazole sulphoxide in Wistar rats. Vet Hum Toxicol 2003, 45, 131-136.
  26. 27. The Joint FAO/WHO Committee on Food Additives (JECFA). Albendazole: in Evaluation of Certain Veterinary Drug Residues in Food. Thirty-fourth Report of the Joint WHO/FAO Expert Committee on Food Additive, WHO, Geneva, 1989, pp. 14-19. Available from: http://apps.who.int/food-additives-contaminantsjecfa-database/chemical.aspx?chemID=478
  27. 28. Wang K., Shindoh H., Inoue T., Horii I.: Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J Toxicol Sci 2002, 27, 229-237.10.2131/jts.27.22912238146
  28. 29. Wilk-Zasadna I., Bernasconi C., Pelkonen O., Coecke S.: Biotransformation in vitro: an essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data. Toxicology 2015, 332, 8-19.10.1016/j.tox.2014.10.00625456264
Language: English
Page range: 313 - 319
Submitted on: Feb 2, 2017
|
Accepted on: Aug 18, 2017
|
Published on: Sep 19, 2017
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2017 Lidia Radko, Maria Minta, Piotr Jedziniak, Sylwia Stypuła-Trębas, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.